Combination therapy with stavudine (d47) plus didanosine (ddI) in childrenwith human immunodeficiency virus infection

Objectives. To evaluate the safety, tolerance, and antiviral activity of co mbination therapy with stavudine (d4T) plus didanosine (ddI) in symptomatic human immunodeficiency virus (HIV)-infected children. Methods. The study enrolled HIV-infected children who successfully complete d Pediatric AIDS Clinical Trials Group (PACTG) protocol 240 (d4T versus zid ovudine [ZDV] monotherapy) without disease progression or who had received ZDV monotherapy by prescription for at least the preceding 6 months. Childr en who had received d4T monotherapy in PACTG 240 were assigned to treatment with d4T plus ddI (arm 1). Children who had received ZDV monotherapy in PA CTG 240 or by prescription were randomized in a double-blind manner to trea tment with either d4T alone (arm 2) or d4T plus ddI (arm 3). patients were followed for 48 weeks each. Results, A total of 108 children were enrolled. The mean age was 5.0 years (range, 1.6 to 11.5 years), with mean baseline plasma HIV RNA concentration and CD4(+) lymphocyte count of 4.6 log(10) copies/mL (range, 2.6 to 5.9 lo g(10) copies/mL) and 819 cells/mu L (range, 8 to 3431 cells/mu L), respecti vely. Both d4T monotherapy and d4T plus ddI combination therapy were well-t olerated, with 96 (89%) patients completing 48 weeks of study treatment. Pl asma HIV RNA concentrations showed larger average declines in arm 3 compare d with arm 2 at study week 12 (0.49 vs 0.18 log(10) copies/mL, respectively ); these average declines were maintained through week 48 (0.51 vs 0.17 log (10) copies/mL, respectively). Fewer than 8% of the patients in any of the treatment arms had plasma HIV RNA concentrations below the limit of quantif ication (200 copies/mL) at any time point. Conclusions. Combination therapy with d4T plus ddI is safe and well-tolerat ed in HIV-infected children, producing durable, but incomplete, suppression of virus replication. This combination of nucleoside antiretroviral agents may provide a valuable backbone to protease inhibitor-containing treatment regimens for HIV-infected children.